GT BioPharma Inc. News
-
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKEĀ® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
-
GT Biopharma Reports Third Quarter 2023 Financial Results
-
GT Biopharma Reports Second Quarter 2023 Financial Results
-
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
-
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update